EUVIMEDEUVIMED entdecken
Open Access

Tumor-specific antibodies elicited by engineered bacteria promote bladder cancer immunotherapy in preclinical mouse models

Mathieu Rouanne iD, Noah Chen iD, Dylan L Mariuzza iD, Zaofeng Yang iD, Fangda Li iD, Kenia de Los Santos-Alexis iD, Thomas M Savage iD, Rosa L Vincent iD, Cathy L Mendelsohn iD, Tal Danino iD, Nicholas Arpaia iD

Science Translational Medicine · 22.07.2026 · 18 (859)

DOI: 10.1126/scitranslmed.adv7600 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Translational Medicine, erschienen am 22.07.2026. Verfasst von Mathieu Rouanne und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology & Immunology, Columbia University, New York, NY 10032, USA. Hauptthemen laut MEDLINE: Immunotherapy, Urinary Bladder Neoplasms, Escherichia coli, Antibodies, Neoplasm. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Cancer Institute, Charles H. Revson Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The intratumoral microbiome has recently emerged as a potential hallmark of cancer, with implications for response or resistance to therapy. Bacteria can either promote or inhibit cancer growth. However, intratumoral bacteria can also be engineered using synthetic biology to remodel the tumor microenvironment. Here, we engineered the probiotic bacterium Escherichia coli Nissle 1917 (EcN) to express the human chemokine CXCL13 (C-X-C motif chemokine ligand 13), a critical component of germinal center (GC) formation. Antibody affinity maturation and class switching are fundamental aspects of adaptive immune response. Both occur primarily in the GCs of secondary lymphoid organs for defense against pathogens. Immune checkpoint blockade (ICB) efficacy is primarily driven by T cells; however, recent studies in mice and humans have shown that humoral immune responses act as critical partners for ICB-mediated antitumor activity. Using orthotopic models of bladder cancer, intravesically delivered engineered CXCL13-expressing EcN colonized bladder tumors and elicited GC responses in bladder tumor–draining lymph nodes after intravesical delivery. When combined with programmed cell death protein 1 (PD-1) blockade, engineered EcN improved antitumor activity in two aggressive, fast-growing, and immunologically cold orthotopic mouse models of bladder cancer. Mechanistically, this antitumor effect was dependent on the presence of CD8 + T cells and CD4 + T follicular helper cells; combination therapy increased tumor-specific antibody responses and promoted long-term survival and protective immunity upon tumor rechallenge. Thus, we demonstrate that synthetically engineered CXCL13-expressing EcN can enhance the efficacy of PD-1 checkpoint blockade immunotherapy by amplifying tumor-specific humoral immunity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunotherapyUrinary Bladder NeoplasmsEscherichia coliAntibodies, NeoplasmAnimalsHumansDisease Models, AnimalMiceCell Line, TumorFemaleChemokine CXCL13Mice, Inbred C57BL

Substanzen

Antibodies, NeoplasmChemokine CXCL13

Autor:innen und Institutionen

  • Department of Microbiology & Immunology, Columbia University, New York, NY 10032, USA.
  • Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY 10032, USA.
  • Department of Biomedical Engineering, Columbia University, New York, NY 10027, USA.
  • Department of Urology, Columbia University, New York, NY 10032, USA.
  • Data Science Institute, Columbia University, New York, NY 10027, USA.

ORCID-Profile: Mathieu Rouanne, Noah Chen, Dylan L Mariuzza, Zaofeng Yang, Fangda Li, Kenia de Los Santos-Alexis, Thomas M Savage, Rosa L Vincent, Cathy L Mendelsohn, Tal Danino, Nicholas Arpaia

Förderung

  • NCI NIH HHS
  • National Cancer Institute
  • Charles H. Revson Foundation

Zitieren

APA

Rouanne, M., Chen, N., Mariuzza, D. L., Yang, Z., Li, F., de Los Santos-Alexis, K., Savage, T. M., Vincent, R. L., Mendelsohn, C. L., Danino, T., & Arpaia, N. (2026). Tumor-specific antibodies elicited by engineered bacteria promote bladder cancer immunotherapy in preclinical mouse models. Science Translational Medicine, 18(859). https://doi.org/10.1126/scitranslmed.adv7600

Vancouver

Rouanne M, Chen N, Mariuzza DL, Yang Z, Li F, de Los Santos-Alexis K, et al. Tumor-specific antibodies elicited by engineered bacteria promote bladder cancer immunotherapy in preclinical mouse models. Science Translational Medicine. 2026;18(859). doi:10.1126/scitranslmed.adv7600

BibTeX
@article{Rouanne2026,
  author = {Rouanne, Mathieu and Chen, Noah and Mariuzza, Dylan L and Yang, Zaofeng and Li, Fangda and de Los Santos-Alexis, Kenia and Savage, Thomas M and Vincent, Rosa L and Mendelsohn, Cathy L and Danino, Tal and Arpaia, Nicholas},
  title = {Tumor-specific antibodies elicited by engineered bacteria promote bladder cancer immunotherapy in preclinical mouse models},
  journal = {Science Translational Medicine},
  year = {2026},
  volume = {18},
  number = {859},
  doi = {10.1126/scitranslmed.adv7600}
}
Kostenlos starten →